The trading price of CRISPR Therapeutics AG (NASDAQ:CRSP) closed lower on Friday, Jan 29, closing at $167.42, -1.03% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $160.44 and $170.62. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.36. In examining the 52-week price action we see that the stock hit a 52-week high of $220.2 and a 52-week low of $32.3. Over the past month, the stock has gained 4.99% in value.
CRISPR Therapeutics AG, whose market valuation is $12.37 Billion at the time of this writing, is expected to release its quarterly earnings report Feb 10, 2021- Feb 15, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$1.27 per share this quarter, however they have predicted annual earnings per share of -$5.02 for 2021 and -$5.31 for 2022. It means analysts are expecting annual earnings per share growth of -5.29% this year and 0.06% next year.
On the technical side, indicators suggest CRSP has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CRSP a recommendation rating is 19. Out of them, 7 rate it a Hold, while 10 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged CRISPR Therapeutics AG (CRSP) as Underperform, while 2 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that CRSP’s price is currently -8.25% off the SMA20 and 6.54% off the SMA50. The RSI metric on the 14-day chart is currently showing 45.55, and weekly volatility stands at 7.95%. When measured over the past 30 days, the indicator reaches 7.77%. CRISPR Therapeutics AG (NASDAQ:CRSP)’s beta value is currently sitting at 2.36, while the Average True Range indicator is currently displaying 13.73. With analysts defining $45-$210 as the low and high price targets, we arrive at a consensus price target of $146.56 for the trailing 12-month period. The current price is about -72.84% off the estimated low and 26.74% off the forecast high, based on this estimate. Investors will be thrilled if CRSP’s share price rises to $160, which is the median consensus price. At that level, CRSP’s share price would be -3.44% above current price.
To see how CRISPR Therapeutics AG stock has been performing in comparison to its peers in the industry, here are the numbers: CRSP stock’s performance was -1.03% in the latest trading, and +216.1% in the past year, while Amgen Inc (AMGN) has traded -2.55% on the day and positioned +6.76% higher than it was a year ago. Another comparable company Bristol-Myers Squibb Company (BMY) saw its stock close -1.38% lower in the most recent trading session but was down -3.73% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -1.03% on the day while its price kept rising at 216.1% over the past year. CRISPR Therapeutics AG has a P/E ratio of 0, compared to Amgen Inc’s 19.47 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has soared -1.93%, while the Dow Jones Industrial also saw a negative seesion, down -2.03% on the day.
An evaluation of the daily trading volume of CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the 3-month average is 1.86 Million. However, this figure has increased over the past 10 days to an average of 2.28 Million.
Currently, records show that 75.13 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 13.71% of outstanding shares, whereas institutions hold 68.49%. The stats also highlight that short interest as of January 14, 2021, stood at 3.64 Million shares, resulting in a short ratio of 1.4 at that time. From this, we can conclude that short interest is 4.84% of the company’s total outstanding shares. It is noteworthy that short shares in January were up slightly from the previous month’s figure, which was 3.61 Million. However, since the stock’s price has seen +8.22% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.